| Huang, He |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT04661020: CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 36 | RoW | CD19 CAR-T cells, CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Non-hodgkin Lymphoma,B Cell | 12/26 | 12/26 | | |
NCT04788472: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL |
|
|
| Completed | 2 | 28 | RoW | CAR-T cells targeting CD19 and CD22 | Zhejiang University, Yake Biotechnology Ltd. | B-Cell Acute Lymphoblastic Leukemia, Adult | 08/24 | 08/24 | | |
NCT05712083: A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 2 | 40 | RoW | BCMA CAR-T cells, BCMA CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma, New Diagnosis Tumor | 04/24 | 04/24 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT05827835: CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases |
|
|
| Recruiting | 2 | 30 | RoW | CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation | Zhejiang University, Yake Biotechnology Ltd. | Hematologic Diseases, Neoplasms | 04/25 | 04/25 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
NCT04944043: A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease |
|
|
| Active, not recruiting | 1/2 | 45 | RoW | TQ05105 Tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 06/23 | 12/24 | | |
NCT06182696: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM |
|
|
| Recruiting | 1/2 | 83 | RoW | OriCAR-017 | OriCell Therapeutics Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma | 11/26 | 08/28 | | |
NCT04740203: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL |
|
|
| Recruiting | 1/2 | 50 | RoW | CAR-T cells targeting CD19 and CD22 | Zhejiang University, Yake Biotechnology Ltd. | B-Cell Acute Lymphoblastic Leukemia, Adult | 01/24 | 01/25 | | |
NCT04790747: Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions |
|
|
| Recruiting | 1/2 | 50 | RoW | CAR-T cells | Zhejiang University, Yake Biotechnology Ltd. | Hematological Malignancies | 03/24 | 03/25 | | |
NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 24 | RoW | BG1805 | Guangzhou Bio-gene Technology Co., Ltd | Leukemia, Myeloid, Acute | 03/25 | 07/25 | | |
NCT04812691: CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma |
|
|
| Completed | 1 | 12 | RoW | JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) | Shanghai Ming Ju Biotechnology Co., Ltd. | Diffuse Large B Cell Lymphoma | 06/21 | 04/23 | | |
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Systemic Lupus Erythematosus, Autoimmune Diseases | 03/22 | 09/22 | | |
NCT04599556: Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy |
|
|
| Recruiting | 1 | 81 | RoW | anti-CD7 CAR-T | Zhejiang University, Yake Biotechnology Ltd. | CD7+ Acute Leukemia, CD7+ Lymphoma | 12/23 | 12/25 | | |
PG-CART-07-001, NCT05170568: PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies |
|
|
| Recruiting | 1 | 22 | RoW | T cell injection targeting CD7 chimeric antigen receptor, PA3-17 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital, Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), First Affiliated Hospital of Zhejiang University School of Medicine | CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | 12/22 | 12/24 | | |
NCT04283006: A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | CD20/CD22 dual Targeted CAR T-cells, CD20/CD22 dual Targeted CAR T-cells injection | He Huang, Yake Biotechnology Ltd. | Relapsed and Refractory, Lymphoid Hematological Malignancies | 05/23 | 05/28 | | |
NCT04532268: A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL |
|
|
| Recruiting | 1 | 72 | RoW | Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell | 08/23 | 08/26 | | |
NCT05731219: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | B7-H3 target, CAR gene modified gdT cell injection, UTAA06 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia | 09/23 | 09/25 | | |
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection, CD19-BCMA CAR-T cells | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T | 10/23 | 04/25 | | |
NCT04532281: A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | Murine CD19 CAR-T cells, Murine CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue | 11/23 | 11/26 | | |
NCT04603872: CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies |
|
|
| Recruiting | 1 | 120 | RoW | CD19/BCMA Targeted CAR T-cells and dasatinib, Administration of CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells, CD19/BCMA Targeted CAR T-cells infusion | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory | 11/23 | 11/26 | | |
NCT04599543: IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 1 | 36 | RoW | IL3 CAR T-cells, IL3 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia | 11/23 | 11/26 | | |
NCT04609241: CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma |
|
|
| Not yet recruiting | 1 | 72 | RoW | CD79b CAR-T Cells | Zhejiang University, Yake Biotechnology Ltd. | Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma | 11/23 | 11/26 | | |
NCT04541368: A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy |
|
|
| Not yet recruiting | 1 | 50 | RoW | CS1 Targeted CAR T-cells, CS1 Targeted CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | Relapse Multiple Myeloma | 12/23 | 12/26 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT04670055: A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 50 | RoW | BCMA Targeted CAR T-cells, BCMA Targeted CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 01/24 | 01/27 | | |
NCT04662294: CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases |
|
|
| Recruiting | 1 | 108 | RoW | CD70 CAR T-cells, CD70 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma | 01/24 | 01/27 | | |
| Recruiting | 1 | 18 | RoW | CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection, BRL-201 | Bioray Laboratories, Institute of Hematology ＆ Blood Diseases Hospital，Chinese Academy of Medical Sciences, Zhejiang University, Wuhan Union Hospital, China | Non-hodgkin Lymphoma,B Cell | 01/24 | 03/24 | | |
NCT04657861: APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 36 | RoW | APRIL CAR-T cells, APRIL CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 08/24 | 08/27 | | |
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis |
|
|
| Recruiting | 1 | 75 | RoW | CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis | 10/24 | 10/24 | | |
NCT05085444: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Scleroderma, Autoimmune Diseases | 10/24 | 10/24 | | |
NCT05085418: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Immune Nephritis, Autoimmune Diseases, Lupus Nephritis | 11/24 | 11/24 | | |
NCT05085431: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Sjogren's Syndrome, Autoimmune Diseases | 11/24 | 11/24 | | |
| Recruiting | 1 | 36 | RoW | CLL1 CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | AML | 11/24 | 11/24 | | |
NCT05239676: Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma |
|
|
| Recruiting | 1 | 50 | RoW | Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells | Zhejiang University, Yake Biotechnology Ltd. | Lymphoma | 12/24 | 12/24 | | |
NCT05239702: Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases |
|
|
| Recruiting | 1 | 75 | RoW | CD7 CAR T-cells, CD7 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Crohn Disease, Ulcerative Colitis, Dermatomyositis, Still Disease, Autoimmune Diseases | 12/24 | 12/24 | | |
NCT05239689: Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies |
|
|
| Recruiting | 1 | 36 | RoW | CD38 CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | AML | 12/24 | 12/24 | | |
NCT05740891: AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 50 | RoW | BCMA CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma | 03/25 | 03/25 | | |
NCT05430945: A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 100 | RoW | BCMA Targeted CAR T-cells, BCMA Targeted CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 06/25 | 06/25 | | |
NCT06084962: A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 40 | RoW | DeepTag-GPRC5D Targeted CAR T-cells, DeepTag-GPRC5D Targeted CAR T-cells injection | He Huang, Yake Biotechnology Ltd. | Relapse/Refractory Multiple Myeloma | 10/26 | 10/26 | | |
| Completed | N/A | 20 | RoW | PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells, PD1-CD19-CART | Bioray Laboratories, First Affiliated Hospital of Zhejiang University | B-cell Lymphoma | 11/21 | 11/23 | | |
| Zhao, Qiong |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
| Fang, Weijia |
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 57 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Biliary Tract Cancer | 11/23 | 06/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
| Completed | 1 | 134 | RoW | CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Solid Tumor | 03/21 | 01/24 | | |
NCT04768608: PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer |
|
|
| Completed | 1 | 3 | RoW | PD1-PSMA-CART cells, Non-viral PD1 integrated anti-PSMA chimeric antigen receptor T cell | Zhejiang University, Bioray Laboratories | Castrate-Resistant Prostate Cancer | 06/22 | 05/23 | | |
NCT05829057: The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 |
|
|
| Recruiting | 1 | 10 | RoW | Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal Antibody | Zhejiang University, Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd | Esophagus Cancer, Bladder Cancer, Liver Cancer, Ovarian Cancer, Small-cell Lung Cancer | 12/24 | 06/25 | | |
PBC039, NCT05396300: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | CEA CAR-T cells | Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd | Colorectal Cancer, Esophageal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Tumor, Recurrent Cancer | 05/24 | 05/25 | | |
NCT05518253: A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | CD70 CAR-T cells | Weijia Fang, MD, Chongqing Precision Biotech Co., Ltd | Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer | 05/24 | 05/25 | | |
| Recruiting | 1 | 21 | RoW | CT0180 Cells, CT0180 humanized anti GPC3 autogenous T Cell injection | Zhejiang University, CARsgen Therapeutics Co., Ltd. | Advanced Hepatocellular Carcinoma | 06/24 | 06/24 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
GT201, NCT05430360: Autologous Tumor-infiltrating Lymphocyte Injection () for the Treatment of Metastatic/Recurrent Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | GT201 | Grit Biotechnology | Solid Tumor | 05/25 | 05/25 | | |
NCT05848999: UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 87 | RoW | UCLM802 Cell Injection (Anti-mesothelin CAR-T cells) | Zhejiang University, UTC Therapeutics Inc. | Mesothelin-positive Advanced Malignant Solid Tumors | 05/25 | 07/25 | | |
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection | Suzhou Immunofoco Biotechnology Co., Ltd | Advanced Digestive System Tumor | 12/25 | 12/25 | | |
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd, Zhejiang University | Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer | 12/26 | 12/27 | | |
| Liu, Lulu |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
